Improved A40926 production from Nonomuraea gerenzanensis using the promoter engineering and the co-expression of crucial genes

Huijun Dong,Xue Yue,Bingyu Yan,Wen Gao,Shuai Wang,Yongquan Li
DOI: https://doi.org/10.1016/j.jbiotec.2020.09.017
IF: 3.595
2020-12-01
Journal of Biotechnology
Abstract:<p>The semi-synthetic antibiotic dalbavancin is clinically used in the treatment of severe infections caused by multidrug resistant Gram-positive pathogens. So far, fermentation has still been the only approach for the production of A40926 in the industrial scale, which is used as the precursor of dalbavancin and biosynthesized by the rare actinomycete <em>Nonomuraea gerenzanensis</em> (<em>N. gerenzanensis</em>). Therefore, it is particularly essential and necessary to enhance the yield of A40926 continually. In this paper, we firstly assessed the activity of 6 heterologous promoters using the enhanced green fluorescence protein (EGFP) reporter system in <em>N. gerenzanensis</em>. Furthermore, the strongest constitutive promoter <em>gapdh</em> confirmed in this study was applied to separately overexpress the total of ten <em>dbv</em> genes involved in the A40926 biosynthesis. PCR and RT-qPCR were successively carried out to verify the mutant and the overexpression of <em>dbv</em> genes. As a consequence, the overexpression of <em>dbv3</em> and <em>dbv20</em> genes both increased the A40926 production remarkably. Based on the above consequences, a mutant strain named N320 laboring the co-expression of <em>dbv3</em> and <em>dbv20</em> was constructed. The results of fermentation showed that the N320 strain enhanced the yield of A40926 from 163 mg/L to 272 mg/L.</p>
biotechnology & applied microbiology
What problem does this paper attempt to address?